Rapport Therapeutics prices $380 million capital raise
Rapport Therapeutics Inc. (RAPP) raised $380M via a public offering of $175M in common stock at $21/share, $25M in pre-funded warrants, and $150M in convertible notes. The company also secured a $30M private placement. Proceeds will fund clinical trials and R&D. The offerings are expected to close by October 30, 2026.
How this was made
The 30-second read
Why it matters
The capital raise secures runway to 2029, but immediate share dilution may depress the stock.
Market read
First disclosure of a large financing package for a mid‑cap biotech; likely short‑term price impact.
What to watch
Potential strategic partnerships or future licensing deals tied to the raised capital are not disclosed.
Background
Rapport Therapeutics is a clinical‑stage biotech developing RAP‑219 for rare diseases.
Ticker impact
Rapport Therapeutics announced pricing of a $380 million capital raise including a $175 million stock offering, $150 million convertible notes and a $30 million private placement.
likely downward pressure as dilution outweighs cash infusion
First‑report of a multi‑hundred‑million raise; market typically reacts negatively to dilution despite long‑term cash runway.
Market effects
Provides biotech sector with a sizable new financing example, may set precedent for other clinical‑stage firms seeking capital.
US biotech financing activity modestly boosted overall capital‑raising sentiment.
Limited to investors tracking biotech funding; no broader macro effect.
Counterpoint
The cash infusion could fund pivotal trials that unlock significant upside, offsetting dilution concerns.
Key entities
- underwriterMorgan Stanley
Joint book‑running manager for the offerings.
- underwriterLeerink Partners
Joint book‑running manager for the offerings.
- underwriterEvercore ISI
Joint book‑running manager for the offerings.
